Mounjaro

Overview

Mounjaro (tirzepatide) is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist developed by Eli Lilly. Originally approved for type 2 diabetes, its weight loss efficacy in the SURMOUNT trial program has made it one of the most closely watched molecules in metabolic medicine. The dual-agonist mechanism targets two incretin pathways simultaneously, producing weight loss results that surpassed existing GLP-1-only therapies in head-to-head comparisons.

Mechanism of Action

Tirzepatide activates both GIP and GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite through central nervous system signaling. The dual mechanism is thought to provide additive metabolic benefits beyond what GLP-1 receptor activation alone achieves, including improved insulin sensitivity and potentially more favorable effects on lipid metabolism.

Clinical Evidence

In SURMOUNT-2, adults with type 2 diabetes and obesity or overweight lost 14.7% of body weight on 15 mg over 72 weeks, versus 3.2% on placebo. In adults without diabetes (SURMOUNT-1), mean weight loss on 15 mg was 20.9%. SURPASS-2 showed greater HbA1c and weight reductions than semaglutide 1 mg in type 2 diabetes. In SURPASS-CVOT, which enrolled more than 13,000 adults with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide for major adverse cardiovascular events (hazard ratio 0.92). Mounjaro's label now includes a cardiovascular risk-reduction indication.

Side Effects & Safety

The most common adverse effects are gastrointestinal: nausea (12% to 18% of patients across doses in the placebo-controlled type 2 diabetes trials, versus 4% on placebo), diarrhea, vomiting, and constipation. Dose escalation helps reduce GI side effects. Mounjaro carries a boxed warning for thyroid C-cell tumors based on rodent studies, plus warnings for pancreatitis and gallbladder disease.

FAQ